Drug maker pushes pause on $89K drug after outcry

In an unexpected move, Marathon Pharmaceuticals announced Monday that it is pausing the roll-out of its now FDA-approved drug for Duchenne muscular dystrophy—which has an $89,000-per-year list price.

Read More

Image courtesy of: Beth Mole